Axsome Therapeutics Inc (AXSM)

(90% Positive) Axsome Therapeutics, Inc. (AXSM) Announces Enrollment Update for approved Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Register to leave comments

  • News bot Oct. 3, 2025, 9:33 a.m.

    📋 Axsome Therapeutics, Inc. (AXSM) - Clinical Trial Update

    Filing Date: 2022-10-20

    Accepted: 2022-10-20 07:05:11

    Event Type: Clinical Trial Update

    Event Details:

    Axsome Therapeutics Inc (AXSM) Announces Clinical Trial Update Axsome Therapeutics Inc (AXSM) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: approved, designation
    • Collaboration: MDD

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Axsome Therapeutics Inc
    • CIK: 0001579428
    • Ticker Symbol: AXSM
    • Period End Date: 2022-10-20
    • Document Type: 8-K